No evidence for glutathione S-transferases , , , , and in breast cancer risk

Breast cancer is a complex disease and in recent years a number of breast cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved. Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes involved in the detoxification of chemical carcinogens and environmental pollutants and play an important role in cell defense mechanisms against oxidative stress. They have been in the spot light for the investigation of a potential association with breast cancer risk but so far, sparse or even no data for a potential contribution of , , , and to breast cancer risk are available. We genotyped _448_C > G (rs2180314), _742_A > C (rs6577), _-832_T > C (rs638820), _-1242_G > A (rs2164624), _419_A > C (rs4925), _-183_A > G (rs2297235), _342_A > G (rs156697), -4378_A > G (rs1046428), and 94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA breast cancer case–control collection of 1021 cases and 1015 controls and performed breast cancer risk association in general and with respect to the stratifications: menopausal status, family history of breast or ovarian cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status. We did not observe any breast cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in breast cancer susceptibility.